Team identifies molecular mechanisms and biomarkers in ovarian cancer
UT Southwestern faculty (USA) have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible...
View ArticleOvarian cancer: Potential therapeutic target identified
A gene called DOT1L appears to play a role in progression and severity of ovarian cancer, and inhibitors of the DOT1L enzyme may offer a new therapeutic approach for the disease, University of Alabama...
View ArticleExploring the microscopic defects causing ovarian cancer to spread
Ovarian cancer devastates more than 20,000 women in the U.S. every year, due in part to its tendency to evade detection and present after metastatic spread. A key element to slowing metastasis is...
View ArticleESMO 2021: FRAME Trial
Highlights on a phase I of dual RAF/MEK inhibitor + FAK inhibitor in ovarian cancer (FRAME)
View ArticleESMO 2021: Maintenance Olaparib in Ovarian Cancer
Highlights on maintenance olaparib in ovarian cancer previously treated with PARPi
View ArticleInnovative ovarian cancer research newly supported by R37 MERIT Award
One of the most impactful advancements during the past decade in treating ovarian cancer is the use of PARP inhibitors (short for poly adenosine diphosphate-ribose polymerase). PARP inhibitors are a...
View ArticleClik here to view.
Study points to new approach to improve ovarian cancer treatment
Immune checkpoint inhibitors are a type of cancer treatment that help the immune system’s T cells recognise and attack tumours. But these immunotherapy drugs aren’t effective against all cancers. In a...
View ArticleClik here to view.
Scientists identify new therapeutic target in ovarian cancer subtype with...
Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute, USA, discovered that...
View ArticleClik here to view.
Scientists uncover potential therapeutic target and biomarker for ovarian cancer
Scientists at the Medical College of Wisconsin (MCW) Cancer Center, USA, and an international team of collaborators have identified a new mechanism of cMYC regulation in ovarian cancer. Although the...
View ArticleClik here to view.
FDA approves “glowing tumour” imaging drug to better identify ovarian cancer...
The U.S. Food and Drug Administration (FDA) today approved an imaging drug known as pafolacianine, which is attracted to ovarian cancer tissue and illuminates it when exposed to fluorescent light,...
View Article
